Italia markets closed

OncoCyte Corporation (0KCC.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
2,3700-1,1250 (-32,19%)
Alla chiusura: 5:13PM GMT
Schermo intero
Chiusura precedente3,4950
Aperto2,3300
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno2,3300 - 2,3700
Intervallo di 52 settimane2,3300 - 2,3700
Volume5.814
Media VolumeN/D
Capitalizzazione215,808M
Beta (5 anni mensile)1,75
Rapporto PE (ttm)N/D
EPS (ttm)-0,4170
Prossima data utili09 nov 2021
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update

    Clinical launch of DetermaIO as first and only immunotherapy response prediction clinical test that comprehensively assesses the tumor microenvironment and consistently outperforms PD-L1 IHC and other biomarkers DetermaIO data in Triple Negative Breast Cancer published in a peer reviewed journal and confirmed in a randomized clinical trial study presented at ESMO; Evidence in fourth tumor type suggests pan-cancer utility DetermaRx test volume grows 65% year over year US transplant IP issued supp

  • GlobeNewswire

    Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test

    DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment In clinical studies to date across multiple tissue types, DetermaIO has consistently proven to be more precise at identifying patients who are immunotherapy responders including those who may have been missed by PDL-1 IHC and other biomarkers IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with th

  • GlobeNewswire

    Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection

    U.S. patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europe Oncocyte’s recently acquired Therasure Transplant Monitor facilitates fast and accurate testing of dd-cfDNA to allow for timely and confident post-transplant treatment decisions IRVINE, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes